CJC-1295 vs ipamorelin vs tesamorelin vs sermorelin

Last updated 2026-07-24

What is the difference between CJC-1295, ipamorelin, tesamorelin, and sermorelin?

All four are peptides that push the body to release its own growth hormone (GH) rather than replacing GH directly. But they aren't interchangeable, and their regulatory histories are wildly different. Sermorelin and tesamorelin are both growth hormone-releasing hormone (GHRH) analogs. They mimic the natural hypothalamic signal that tells the pituitary to make and release GH. Sermorelin is a 29-amino acid fragment of native GHRH, the shortest sequence known to retain full biologic activity ^[1]. Tesamorelin is a modified GHRH analog that the FDA actually approved, under the brand name Egrifta, for HIV-associated lipodystrophy. CJC-1295 is also a GHRH analog, chemically related to sermorelin and tesamorelin, but modified for a longer half-life. It comes in two versions: one without a chemical modification called DAC (drug affinity complex), which behaves a lot like sermorelin, and one with DAC, which extends action for days rather than hours. Ipamorelin is a different animal entirely. It's a growth hormone-releasing peptide (GHRP), a ghrelin-receptor agonist, not a GHRH analog. It works through a separate receptor pathway and is often paired with a GHRH analog in research settings. None of these four is human growth hormone (HGH) itself. HGH (somatropin) is the hormone; these peptides are upstream signals that try to get your own pituitary to make more of it.

How does each peptide actually work in the body?

GHRH analogs (sermorelin, tesamorelin, CJC-1295) bind the GHRH receptor on pituitary somatotroph cells, triggering the same signaling cascade that natural GHRH uses to stimulate GH synthesis and pulsatile release. Because this pathway still depends on an intact pituitary and still respects the body's negative feedback loops, dosing a GHRH analog generally cannot force GH output past what the pituitary is physiologically capable of producing, unlike injecting HGH directly. Ipamorelin works differently. It binds the ghrelin receptor (GHS-R1a), which triggers GH release through a separate mechanism and, notably, has much weaker effects on cortisol and prolactin than older GHRPs like GHRP-6, which is the main reason it built a reputation as the 'cleaner' secretagogue in research circles. Combining a GHRH analog with a ghrelin-receptor agonist (for example, CJC-1295 with ipamorelin) is a common research pairing because the two mechanisms are additive rather than redundant. That combination shows up constantly in online sourcing forums, but it's worth being clear: additive stimulation in a research setting is not the same thing as a demonstrated safe, dosed clinical protocol in humans. A 2020 review in Translational Andrology and Urology on growth hormone secretagogues in hypogonadal men lays out this GH-IGF-1 axis rationale in detail, and a related 2017 study found that GH secretagogue treatment raised serum IGF-1 levels in hypogonadal men ^[2][3], which is the expected downstream marker if the pituitary is responding.

Which of these four has FDA approval or a real regulatory history?

This is the single biggest differentiator, and it's not close. Tesamorelin is FDA-approved, sold as Egrifta, specifically for reducing excess abdominal fat in HIV patients with lipodystrophy. You can look it up directly in Drugs@FDA [FDA Drugs@FDA database]. That approval came with a defined clinical trial package the other three peptides never had. Sermorelin has real history too, just not current approval. It was marketed in the US under the brand name Geref for diagnosing and treating growth hormone deficiency in children, and later in adults. Geref was discontinued by the manufacturer for business reasons, not pulled for a safety failure. A 2006 review in Clinical Interventions in Aging frames sermorelin as a physiologic alternative to direct HGH replacement for adult-onset GH insufficiency ^[4], and a 1999 review in BioDrugs covers its original approved use diagnosing and treating pediatric idiopathic GH deficiency ^[5]. Today, sermorelin is available through compounding pharmacies rather than as an FDA-approved finished product, and it appears on FDA's bulk drug substance frameworks that govern what compounders can legally use [FDA 503A bulk substances; 21 CFR 216.23]. CJC-1295 and ipamorelin have never had an FDA-approved drug product under any brand name. There's no Drugs@FDA entry for either. They exist almost entirely as research chemicals or compounded preparations, and the compounding legal status for both is murkier than for sermorelin. Under 21 U.S.C. 353a, compounders can only use bulk substances that meet specific criteria, and not every peptide sold online as 'CJC-1295' or 'ipamorelin' is being handled by a pharmacy operating inside that framework at all.

cjc-1295 vs ipamorelin vs tesamorelin vs sermorelin: side-by-side comparison

How is each one dosed?

Dosing here has to be split into 'what a prescriber uses in a legitimate, compounded protocol' versus 'what's floating around research-chemical forums,' because those two data sets aren't remotely equivalent in quality. Sermorelin, when prescribed by a clinician working with a compounding pharmacy, is typically dosed as a nightly subcutaneous injection, timed to work with the body's natural nocturnal GH pulse. Doses in published pediatric and adult literature ranged from roughly 0.03 mg/kg up in weight-based pediatric protocols to fixed adult doses discussed in older adult GH insufficiency literature ^[4][5]. Your prescriber will land on a specific number based on your labs and goals; there's no single 'standard' dose that fits everyone. Tesamorelin's approved dosing (as Egrifta) is 2 mg by subcutaneous injection once daily, per its FDA-approved labeling, reconstituted from the packaged vial. CJC-1295 and ipamorelin dosing in circulation online is almost entirely derived from research-chemical vendor literature and anecdote, not from peer-reviewed dose-finding trials in patients. That's a real gap. If a source hands you a precise CJC-1295 microgram protocol with total confidence, ask where the number came from. Often, the honest answer is 'nowhere clinical.'

What does the actual evidence say about each peptide's effects?

Evidence quality drops sharply as you move from sermorelin/tesamorelin to CJC-1295/ipamorelin. Sermorelin has the longest track record. Beyond its original pediatric approval, a 2021 paper in Annals of Translational Medicine explored sermorelin as a potentially effective drug in recurrent glioma, an early-stage, non-GH-deficiency application worth noting precisely because it shows researchers are still finding new angles on an old, well-characterized molecule ^[9]. That's not a claim it treats glioma in practice; it's a signal the molecule has ongoing research interest beyond its original use. Tesamorelin's evidence base is the strongest of the four for a defined outcome (reducing visceral fat in HIV lipodystrophy), because that's literally what its FDA approval was built on. CJC-1295 and ipamorelin show up far more in analytical chemistry and anti-doping literature than in outcome trials. Multiple 2020s papers focus on detecting these peptides in blood or urine rather than measuring what they do therapeutically ^{[6][10][11][7][12][8]}, which tells you where the scientific attention has actually gone: catching people using them in sport, not proving clinical benefit. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews looked at therapeutic peptides broadly in orthopaedic applications and flagged the general challenge of translating peptide research into approved treatments ^[1]. A related 2026 Sports Medicine review on peptide therapies for musculoskeletal injuries and athletic performance likewise scrutinized safety and efficacy claims for both approved and unapproved peptides ^[13], which is exactly the bucket CJC-1295 and ipamorelin fall into: unapproved, still being studied for basic safety questions, not proven benefit. If you want a fuller picture of what's published specifically on sermorelin outcomes, see sermorelin peptide before and after.

Is sermorelin better than HGH, or the other way around?

Honestly, it depends what you need, and sermorelin isn't automatically the 'gentler' win it's often marketed as. HGH (somatropin) is the hormone itself, injected directly. It bypasses the pituitary entirely, works regardless of how well your own GH axis functions, and produces more predictable, larger increases in circulating GH and IGF-1. That's exactly why HGH is the correct choice for confirmed, severe GH deficiency, and why it's not a good idea to use it if your pituitary is basically fine, since you're overriding a control system that would otherwise regulate GH output on its own. Sermorelin only works if your pituitary can still respond to a GHRH signal. It produces a smaller, more physiologic rise in GH, generally with more moderate IGF-1 increases than direct HGH replacement, and it preserves the pulsatile, feedback-regulated pattern of natural GH release rather than flooding the system. A 2006 review makes exactly this argument, that sermorelin represents a more physiologic approach to adult-onset GH insufficiency compared with direct HGH replacement ^[4]. Where sermorelin is the weaker choice: if you have significant pituitary damage (from tumor, radiation, or surgery) that has wiped out somatotroph function, no amount of GHRH signal will help, because there's no functioning cell left to respond to it. In that situation, HGH is the only option that works. Sermorelin also can't match HGH's IGF-1 ceiling, so if your prescriber's goal is a specific IGF-1 target for a defined deficiency, HGH gets there more reliably. For most adults being screened for age-related GH decline (not documented deficiency), the honest answer is that neither drug has been shown by good evidence to reverse aging or meaningfully improve body composition beyond what diet, resistance training, and sleep already do. That's a fair thing for a prescriber to tell you, and if they don't, ask why.

What are the real safety differences between the four?

Sermorelin and tesamorelin, as GHRH analogs used at physiologic-style doses, generally carry a lower risk of pushing GH/IGF-1 to supraphysiologic levels than direct HGH, because the pituitary's own feedback loops stay intact. Common reported effects across GHRH analog use include injection site reaction, flushing, and headache; tesamorelin's FDA labeling also documents joint-related symptoms. CJC-1295 (particularly the DAC version) and ipamorelin carry an added layer of uncertainty: because neither has completed the kind of large, FDA-reviewed safety trial tesamorelin has, dosing safety margins, long-term effects, and rare adverse events are much less mapped out. A 2026 case report in Frontiers in Surgery described anterior cervical osteophyte-related dysphagia in a long-term growth hormone user, illustrating that chronic overstimulation of the GH axis, however it's achieved, is not risk-free over years . A 2026 review in Frontiers in Endocrinology on performance-enhancing peptides modulating the GH-IGF-1 axis specifically raises the gap between clinical evidence and the reality of patients self-administering these compounds without medical supervision . There's also a sourcing-safety issue distinct from the drug's own pharmacology. A 2016 investigation in Drug Testing and Analysis ('Operation Resistance') documented falsified biopharmaceutical injectables circulating in Europe ^[14], a reminder that unregulated peptide markets carry contamination and mislabeling risk on top of whatever the molecule itself does. For a full breakdown of what's actually documented for sermorelin specifically, read sermorelin long-term side effects.

Can you legally buy CJC-1295 or ipamorelin the way you can buy sermorelin?

Not on the same footing. Sermorelin is on FDA's radar as a substance nominated for use in compounding under Section 503A, and compounding pharmacies operate under a specific legal framework (21 U.S.C. 353a; 21 CFR 216.23 for the 503A bulks list, 21 CFR 216.24 for 503B) that requires a prescription and physician oversight [FDA bulk substances page]. CJC-1295 and ipamorelin don't have the same clean compounding history sermorelin does, and much of what's sold under those names online comes from 'research chemical' sellers explicitly labeled 'not for human consumption,' which sidesteps FDA drug regulation entirely rather than working within it. That labeling isn't a technicality; it means there's no manufacturing quality oversight, no guaranteed sterility, and no prescriber checking your labs. Tesamorelin, because it's FDA-approved as Egrifta, is available by prescription through normal pharmacy channels for its approved indication. If you're going to use any of these compounds, the practical safety difference between a compounded, prescriber-reviewed product and an unregulated research-chemical vial is enormous. See best place to buy sermorelin and sermorelin reviews for what to look for in a legitimate source.

Can sermorelin and tesamorelin (or CJC-1295/ipamorelin) be combined?

Combining a GHRH analog with a ghrelin-receptor agonist (like sermorelin or CJC-1295 with ipamorelin) is a common pattern in research literature because the two act on different receptors, but 'mechanistically additive' is not the same claim as 'clinically proven safe and effective as a combination in humans.' Stacking sermorelin with tesamorelin specifically is a different question people ask a lot, since both are GHRH analogs working the same receptor, which raises the question of whether combining them adds anything over using one alone at an adequate dose. We cover that question directly in can stack tesamorelin and sermorelin. Whatever combination you're considering, the honest starting point is a prescriber who can check your IGF-1 and other labs before and during treatment, not a forum protocol.

How do anti-doping labs and drug tests treat these peptides?

All four show up in anti-doping science, which is itself informative: regulators have needed to build detection methods precisely because these peptides are being used outside legitimate medical settings, including in sport. Multiple analytical chemistry papers from 2015 through 2026 describe methods (immunoaffinity purification, LC-HRMS/MS, capillary electrophoresis, UHPLC-MS/MS) built specifically to catch GHRH analogs and related peptides in blood, plasma, and urine at very low concentrations, down to low picogram-per-milliliter levels in some assays ^{[6][10][15][7][12][16][8][17]}. A 2021 review in Drug Testing and Analysis specifically tracks advances in detecting GHRH synthetic analogs ^[6], and a 2026 critical review in The Journal of Sports Medicine and Physical Fitness frames peptide and peptide-analog use in recreational and professional sport and bodybuilding as a genuine, ongoing doping concern ^[18]. If you're a competitive athlete under a testing program, treat any of these four peptides, sermorelin included, as something that could trigger a positive test. This isn't a gray area regulators have overlooked; it's an active area of assay development specifically because use is real.

Which one should you actually ask your prescriber about?

If you have documented, lab-confirmed adult GH deficiency and want the option with the deepest safety and regulatory history, sermorelin (through a compounding pharmacy, prescriber-reviewed) or tesamorelin (FDA-approved, for its specific indication) are the two worth a real conversation. Sermorelin Co's editorial position is straightforward: work with a licensed prescriber who orders baseline IGF-1 and clinical labs, explains realistic expectations, and sources through a pharmacy operating under the 503A/503B compounding framework rather than an unregulated research-chemical seller. CJC-1295 and ipamorelin are harder to recommend with the same confidence. Not because they definitely don't work through their proposed mechanisms, but because the human safety and dosing data simply isn't at the same level, and neither has ever gone through FDA review as a finished drug product. If a seller offers you either with zero mention of that gap, that's a red flag about the source, more than the compound. Start with the basics at sermorelin if you're new to how GHRH therapy works, then talk to a prescriber before choosing between any of these four.

Frequently asked questions

What is the main difference between CJC-1295 and sermorelin?

Both are GHRH analogs that stimulate the pituitary to release growth hormone, but CJC-1295 (especially the DAC version) is chemically modified for a much longer half-life, lasting days instead of the roughly 10-20 minutes typical of sermorelin. Sermorelin also has a documented FDA regulatory history as the discontinued brand Geref; CJC-1295 has never had FDA approval.

Is ipamorelin a GHRH like sermorelin?

No. Ipamorelin is a ghrelin-receptor agonist (a GHRP), a different drug class that works through a separate receptor than sermorelin, tesamorelin, and CJC-1295, which are all GHRH analogs. Ipamorelin is often combined with a GHRH analog in research settings because the two mechanisms are considered additive.

Is tesamorelin FDA-approved and the others aren't?

Yes. Tesamorelin is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-associated lipodystrophy, verifiable in the Drugs@FDA database. Sermorelin was previously FDA-approved as Geref (discontinued by the manufacturer, not withdrawn for safety) but has no current approved brand. CJC-1295 and ipamorelin have never had an FDA-approved product.

Why was Geref (sermorelin) discontinued?

Geref was the branded, FDA-approved sermorelin product marketed for diagnosing and treating growth hormone deficiency. It was discontinued for business reasons, not pulled from the market over a safety finding. Sermorelin remains legally available today through compounding pharmacies under FDA's 503A bulk drug substance framework.

Is sermorelin as effective as HGH?

Not in raw potency. Sermorelin produces a smaller, more physiologic rise in GH and IGF-1 because it depends on your pituitary still working; HGH bypasses the pituitary and delivers the hormone directly, more reliably raising GH/IGF-1 regardless of pituitary function. Sermorelin is the better fit for mild insufficiency with intact pituitary function; HGH is needed for severe deficiency or pituitary damage.

Can you stack CJC-1295 with ipamorelin?

This combination shows up often in research and online forums because CJC-1295 (GHRH pathway) and ipamorelin (ghrelin-receptor pathway) act on different receptors, making the stimulation theoretically additive. But there's no large, FDA-reviewed human trial proving this specific combination's safety or effectiveness; most supporting literature is mechanistic or analytical, not outcome-based.

Which of these four peptides has the most human safety data?

Tesamorelin, because its FDA approval as Egrifta required a completed clinical trial package. Sermorelin is second, with decades of published use in pediatric GH deficiency diagnosis and adult GH insufficiency treatment. CJC-1295 and ipamorelin have comparatively little published outcome data; most literature on them focuses on detecting the compounds, not proving clinical benefit.

Do CJC-1295 and ipamorelin show up on drug tests?

Yes, and detecting them is an active area of anti-doping science. Multiple 2020s analytical chemistry papers describe LC-MS/MS, immunoaffinity, and capillary electrophoresis methods built specifically to catch GHRH analogs and related peptides in blood and urine at very low concentrations, precisely because these compounds are used to evade testing in sport.

Is it legal to buy CJC-1295 or ipamorelin online?

The legal picture is murkier than for sermorelin. Much of what's sold online as CJC-1295 or ipamorelin comes labeled 'research use only, not for human consumption,' which sidesteps FDA drug regulation rather than complying with it. Sermorelin, by contrast, is compounded under a defined legal framework (21 U.S.C. 353a) requiring a prescription.

What's the typical sermorelin dose compared to tesamorelin?

Tesamorelin's FDA-approved dose (as Egrifta) is 2 mg subcutaneously once daily. Sermorelin doses vary by prescriber and patient, historically weight-based in pediatric protocols and individualized in adults, typically given as a nightly subcutaneous injection timed with the body's natural overnight GH pulse.

Can sermorelin help with anti-aging or muscle gain?

There's no strong clinical evidence that sermorelin reverses aging or reliably builds muscle in adults without documented GH deficiency. Its evidence base is built around diagnosing and treating actual GH deficiency. Be skeptical of any source promising anti-aging or bodybuilding results; that's not what the approved or historical data supports.

Does CJC-1295 with DAC last longer than regular CJC-1295?

Yes. The DAC (drug affinity complex) modification is specifically designed to extend CJC-1295's half-life from hours to several days by binding to albumin in the bloodstream, slowing its clearance. Regular CJC-1295 without DAC behaves closer to a short-acting GHRH analog like sermorelin.

Why do so many studies on CJC-1295 and ipamorelin focus on detection instead of treatment?

Because neither compound has gone through FDA drug development, the scientific attention on them has concentrated in anti-doping and forensic chemistry, building assays to detect misuse in athletes, rather than in the clinical trial pipeline that produces treatment efficacy data. That's a meaningful gap compared to sermorelin and tesamorelin.

Sources

1. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics flags the challenge of translating peptide research into approved treatments.
2. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): Review evaluates safety and efficacy of approved versus unapproved peptide therapies for musculoskeletal injuries and athletic performance.
3. Drug Testing and Analysis, 2021 (PMID 34665524): Reviews advances in detecting synthetic GHRH analogs, reflecting the anti-doping focus on these compounds.
4. Translational Andrology and Urology, 2020 (PMID 32257855): Reviews the role of growth hormone secretagogues in managing body composition in hypogonadal men via the GH-IGF-1 axis.
5. Clinical Interventions in Aging, 2006 (PMID 18046908): Argues sermorelin is a more physiologic approach than direct HGH replacement for adult-onset GH insufficiency.
6. Analytical Biochemistry, 2023 (PMID 37806509): Describes a cationic exchange SPE combined with UHPLC-MS/MS method for detecting GHRHs in urine.
7. Annals of Translational Medicine, 2021 (PMID 33842627): Explores sermorelin as a potentially effective drug for patients with recurrent glioma, an emerging research area beyond its original use.
8. BioDrugs, 1999 (PMID 18031173): Reviews sermorelin's original approved use in diagnosing and treating pediatric idiopathic growth hormone deficiency.
9. Journal of Pharmaceutical and Biomedical Analysis, 2022 (PMID 35298973): Describes an antibody-free ultrafiltration nanoLC-HRMS/MS assay detecting GHRHs in urine at low picogram-per-mL concentrations.
10. The Journal of Sports Medicine and Physical Fitness, 2026 (PMID 41880199): Critical review frames peptide and peptide-analog drug use as an ongoing doping concern in recreational and professional sport and bodybuilding.
11. Biomedical Chromatography, 2023 (PMID 37688464): Studies enzymatic and serum stability/degradation of GHRP and GHRH-related doping peptides, including compounds like CJC-1295.
12. Journal of Mass Spectrometry, 2024 (PMID 38197510): Describes chromatographic-mass spectrometric methods for analyzing peptidic analytes (2-10 kDa) in doping control urine samples.
13. Drug Testing and Analysis, 2015 (PMID 26382721): Describes an expanded immunoaffinity/LC-HRMS/MS test method for peptides over 2 kDa used in doping detection.
14. Journal of Pharmaceutical and Biomedical Analysis, 2026 (PMID 41138283): Describes nano-LC coupled to quadrupole/orbitrap mass spectrometry for analyzing GHRH and its analogs in urine.
15. American Journal of Men's Health, 2017 (PMID 28830317): Found growth hormone secretagogue treatment raises serum IGF-1 levels in hypogonadal men.
16. Analytical and Bioanalytical Chemistry, 2016 (PMID 26879649): Describes qualitative identification of GHRHs in human plasma using immunoaffinity purification and LC-HRMS/MS.
17. Drug Testing and Analysis, 2016 (PMID 26456392): Documents falsified biopharmaceutical injectables circulating in Europe, illustrating unregulated peptide market risks.
18. Frontiers in Surgery, 2026 (PMID 42465868): Case report describes anterior cervical osteophyte-related dysphagia in a long-term growth hormone user.
19. Frontiers in Endocrinology, 2026 (PMID 42395176): Reviews the gap between clinical evidence and patient self-administration of performance-enhancing peptides modulating the GH-IGF-1 axis.
20. Electrophoresis, 2023 (PMID 36787346): Describes capillary electrophoresis methods for separating enantiomeric GHRH analogs, part of ongoing detection science for these compounds.